

# Basic Drug List Updates

July 2021

TRADE NAME (generic name)	Brand/Generic Product	Description of Change
ATRIPLA (efavirenz-emtricitabine-tenofovir df tab 600-200-300 mg)	Brand	Removal, Non-Preferred Status, generics available
CARBAGLU (carglumic acid tab 200 mg)	Brand	Addition, Preferred Status
KESIMPTA (ofatumumab soln auto-injector 20 mg/0.4ml)	Brand	Addition, Preferred Status
LATUDA (lurasidone hcl tab 120 mg)	Brand	Addition, Preferred Status
LATUDA (lurasidone hcl tab 20 mg)	Brand	Addition, Preferred Status
LATUDA (lurasidone hcl tab 40 mg)	Brand	Addition, Preferred Status
LATUDA (lurasidone hcl tab 60 mg)	Brand	Addition, Preferred Status
LATUDA (lurasidone hcl tab 80 mg)	Brand	Addition, Preferred Status
MAYZENT STARTER PACK (siponimod fumarate tab 0.25 mg (12) starter pack)	Brand	Addition, Preferred Status
NYVEPRIA (pegfilgrastim-apgf soln prefilled syringe 6 mg/0.6ml)	Brand	Addition, Preferred Status
OZEMPIC (semaglutide soln pen-inj 1 mg/dose (4 mg/3ml))	Brand	Addition, Preferred Status
PLEGRIDY (peginterferon beta-1a im soln prefilled syr 125 mcg/0.5ml)	Brand	Addition, Preferred Status
REDITREX (methotrexate soln prefilled syringe 10 mg/0.4ml)	Brand	Addition, Preferred Status
REDITREX (methotrexate soln prefilled syringe 12.5 mg/0.5ml)	Brand	Addition, Preferred Status
REDITREX (methotrexate soln prefilled syringe 15 mg/0.6ml)	Brand	Addition, Preferred Status
REDITREX (methotrexate soln prefilled syringe 17.5 mg/0.7ml)	Brand	Addition, Preferred Status
REDITREX (methotrexate soln prefilled syringe 20 mg/0.8ml)	Brand	Addition, Preferred Status
REDITREX (methotrexate soln prefilled syringe 22.5 mg/0.9ml)	Brand	Addition, Preferred Status
REDITREX (methotrexate soln prefilled syringe 25 mg/ml)	Brand	Addition, Preferred Status
REDITREX (methotrexate soln prefilled syringe 7.5 mg/0.3ml)	Brand	Addition, Preferred Status
TRUVADA (emtricitabine-tenofovir disoproxil fumarate tab 100-150 mg)	Brand	Removal, Non-Preferred Status, generics available
TRUVADA (emtricitabine-tenofovir disoproxil fumarate tab 133-200 mg)	Brand	Removal, Non-Preferred Status, generics available
TRUVADA (emtricitabine-tenofovir disoproxil fumarate tab 167-250 mg)	Brand	Removal, Non-Preferred Status, generics available
TRUVADA (emtricitabine-tenofovir disoproxil fumarate tab 200-300 mg)	Brand	Removal, Non-Preferred Status, generics available
VIMPAT (lacosamide oral solution 10 mg/ml)	Brand	Addition, Preferred Status
VIMPAT (lacosamide tab 100 mg)	Brand	Addition, Preferred Status
VIMPAT (lacosamide tab 150 mg)	Brand	Addition, Preferred Status
VIMPAT (lacosamide tab 200 mg)	Brand	Addition, Preferred Status
VIMPAT (lacosamide tab 50 mg)	Brand	Addition, Preferred Status
XELJANZ (tofacitinib citrate oral soln 1 mg/ml (base equivalent))	Brand	Addition, Preferred Status
XTANDI (enzalutamide tab 40 mg)	Brand	Addition, Preferred Status
XTANDI (enzalutamide tab 80 mg)	Brand	Addition, Preferred Status
ZOKINVY (lonafarnib cap 50 mg)	Brand	Addition, Preferred Status
ZOKINVY (lonafarnib cap 75 mg)	Brand	Addition, Preferred Status

Blue Cross and Blue Shield of Illinois (BCBSIL), Blue Cross and Blue Shield of Montana (BCBSMT), Blue Cross and Blue Shield of New Mexico (BCBSNM), Blue Cross and Blue Shield of Oklahoma (BCBSOK), and Blue Cross and Blue Shield of Texas (BCBSTX) are Divisions of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association. BCBSIL, BCBSMT, BCBSNM, BCBSOK, and BCBSTX contract with Prime Therapeutics to provide pharmacy benefit management and related other services. BCBSIL, BCBSMT, BCBSNM, BCBSOK, and BCBSTX, as well as several independent Blue Cross and Blue Shield Plans, have an ownership interest in Prime Therapeutics LLC.